HK1202431A1 - Humanized pan-her antibody compositions pan-her - Google Patents
Humanized pan-her antibody compositions pan-herInfo
- Publication number
- HK1202431A1 HK1202431A1 HK15103006.9A HK15103006A HK1202431A1 HK 1202431 A1 HK1202431 A1 HK 1202431A1 HK 15103006 A HK15103006 A HK 15103006A HK 1202431 A1 HK1202431 A1 HK 1202431A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pan
- humanized
- antibody compositions
- antibody
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261641756P | 2012-05-02 | 2012-05-02 | |
US201361809159P | 2013-04-05 | 2013-04-05 | |
PCT/IB2013/001027 WO2013164689A2 (fr) | 2012-05-02 | 2013-05-02 | Compositions d'anticorps pan-her humanisés |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202431A1 true HK1202431A1 (en) | 2015-10-02 |
Family
ID=48626482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15103006.9A HK1202431A1 (en) | 2012-05-02 | 2015-03-24 | Humanized pan-her antibody compositions pan-her |
Country Status (12)
Country | Link |
---|---|
US (3) | US9527913B2 (fr) |
EP (1) | EP2844675B1 (fr) |
JP (1) | JP6325527B2 (fr) |
KR (1) | KR101933990B1 (fr) |
CN (1) | CN104428318B (fr) |
AU (1) | AU2013255537B2 (fr) |
BR (1) | BR112014027291A2 (fr) |
CA (1) | CA2872226A1 (fr) |
HK (1) | HK1202431A1 (fr) |
IL (1) | IL235386A0 (fr) |
MX (1) | MX358728B (fr) |
WO (1) | WO2013164689A2 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003222568B2 (en) | 2002-01-11 | 2009-05-07 | Bioasis Technologies, Inc. | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
CA2880162C (fr) | 2012-07-31 | 2023-04-04 | Bioasis Technologies, Inc. | Proteines de maladie de stockage lysosomal dephosphorylees et leurs procedes d'utilisation |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
NZ711373A (en) | 2013-03-13 | 2020-07-31 | Bioasis Technologies Inc | Fragments of p97 and uses thereof |
US20160237163A1 (en) * | 2013-10-02 | 2016-08-18 | Suri Technologies Ltd. | Patient-specific immunotherapy for treating heterogeneous tumors |
CN109320612B (zh) | 2013-11-19 | 2020-10-27 | 荣昌生物制药(烟台)有限公司 | 抗her2抗体及其缀合物 |
EP3102608B1 (fr) | 2014-02-03 | 2019-09-18 | Bioasis Technologies Inc. | Protéines de fusion p97 |
AU2015219339B2 (en) | 2014-02-19 | 2020-03-05 | Bioasis Technologies Inc. | P97-IDS fusion proteins |
TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
EP3191523B1 (fr) | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions et procédés de traitement d'un cancer résistant à un inhibiteur de la tyrosine kinase (tki) |
MX2017015690A (es) | 2015-06-05 | 2018-07-06 | Novartis Ag | Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos. |
MX2018003633A (es) * | 2015-09-25 | 2018-08-01 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso. |
CN105131116B (zh) * | 2015-09-25 | 2018-10-09 | 中国人民解放军第四军医大学 | 靶向HER2的人源化改造的可内化单链抗体P1h3及制备方法和应用 |
ITUA20162242A1 (it) | 2016-04-01 | 2017-10-01 | St Biochimico Italiano Giovanni Lorenzini Spa | Un nuovo anticorpo anti-erbb2 |
EP3241847A1 (fr) * | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Anticorps de liaison her-2 |
WO2017194554A1 (fr) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Polythérapies pour le traitement du cancer |
CN117982673A (zh) * | 2017-02-28 | 2024-05-07 | 第一三共株式会社 | 抗her3抗体-药物偶联物的应用 |
JP2020513009A (ja) | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブSymphogen A/S | Pd−1、tim−3、およびlag−3を標的とする併用治療 |
GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
CN114426578A (zh) * | 2019-02-14 | 2022-05-03 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
BR112021016094A2 (pt) * | 2019-02-14 | 2021-10-26 | Merus N.V. | Combinações de porções de ligação que se ligam ao egfr, her2 e her3 |
CN111635457A (zh) * | 2020-05-22 | 2020-09-08 | 上海药明生物医药有限公司 | 一种纳米抗体人源化的方法 |
IL299329A (en) * | 2020-06-24 | 2023-02-01 | Prothena Biosciences Ltd | Antibodies recognizing sortilin |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
NZ537660A (en) | 2002-07-15 | 2008-12-24 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies |
CN100408097C (zh) * | 2002-10-10 | 2008-08-06 | 默克专利有限公司 | 双特异性抗erb-b抗体及其在肿瘤治疗中的用途 |
AU2003276084B2 (en) | 2002-10-10 | 2009-07-09 | Merck Patent Gmbh | Bispecific anti-Erb-B antibodies and their use in tumor therapy |
WO2004061104A2 (fr) | 2003-01-07 | 2004-07-22 | Symphogen A/S | Methode de production de proteines polyclonales de recombinaison |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
WO2005099756A2 (fr) | 2004-04-08 | 2005-10-27 | Agus David B | Antagonistes d'erbb pour le traitement de la douleur |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
AU2006332212B8 (en) | 2006-01-04 | 2013-05-30 | Institut National De La Sante Et De La Recherche Medicale | Combination therapy using anti-EGFR and anti-HER2 antibodies |
US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
WO2008031531A1 (fr) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Thérapie antitumorale avec une combinaison d'anticorps anti-her2 |
DK2129396T3 (da) | 2007-02-16 | 2013-11-25 | Merrimack Pharmaceuticals Inc | Antistoffer mod ErbB3 og anvendelser deraf |
RU2459868C2 (ru) | 2007-03-01 | 2012-08-27 | Симфоген А/С | Способ клонирования когнатных антител |
KR101676622B1 (ko) | 2007-03-01 | 2016-11-17 | 심포젠 에이/에스 | 재조합 항-표피 성장 인자 수용체 항체 조성물 |
BRPI0812091A2 (pt) | 2007-05-25 | 2014-10-14 | Symphogen As | Método para fabricar uma proteína policlonal recombinante |
JP2008289483A (ja) | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
RU2010147652A (ru) | 2008-04-23 | 2012-05-27 | Симфоген А/С (Dk) | Способы производства поликлонального белка |
KR101706255B1 (ko) | 2008-08-29 | 2017-02-14 | 심포젠 에이/에스 | 재조합 항-표피 성장 인자 수용체 항체 조성물 |
EP2335068A4 (fr) | 2008-10-06 | 2012-07-25 | Symphogen As | Procédé d'identification et de sélection de candidats médicaments pour des produits médicamenteux combinatoires |
EP2408817B1 (fr) | 2009-03-20 | 2016-03-16 | F.Hoffmann-La Roche Ag | Anticorps anti-her di-spécifiques |
ES2655737T3 (es) * | 2009-11-13 | 2018-02-21 | Daiichi Sankyo Europe Gmbh | Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3 |
US20110129588A1 (en) | 2009-11-30 | 2011-06-02 | Metropolis Industries, Llc | Process for preparation of a gelatinous food product containing alcohol |
US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
TW201141519A (en) * | 2010-03-04 | 2011-12-01 | Symphogen As | Anti-HER2 antibodies and compositions |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
DK2635604T3 (en) | 2010-11-01 | 2017-02-27 | Symphogen As | PAN-HER-ANTIBODY COMPOSITION |
CN103562226A (zh) | 2011-03-11 | 2014-02-05 | 梅里麦克制药股份有限公司 | 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌 |
-
2013
- 2013-05-02 KR KR1020147033605A patent/KR101933990B1/ko active IP Right Grant
- 2013-05-02 MX MX2014013213A patent/MX358728B/es active IP Right Grant
- 2013-05-02 WO PCT/IB2013/001027 patent/WO2013164689A2/fr active Application Filing
- 2013-05-02 CN CN201380033627.0A patent/CN104428318B/zh not_active Expired - Fee Related
- 2013-05-02 BR BR112014027291A patent/BR112014027291A2/pt not_active Application Discontinuation
- 2013-05-02 JP JP2015509512A patent/JP6325527B2/ja active Active
- 2013-05-02 EP EP13729074.8A patent/EP2844675B1/fr active Active
- 2013-05-02 US US14/398,441 patent/US9527913B2/en not_active Expired - Fee Related
- 2013-05-02 CA CA2872226A patent/CA2872226A1/fr not_active Abandoned
- 2013-05-02 AU AU2013255537A patent/AU2013255537B2/en not_active Ceased
-
2014
- 2014-10-29 IL IL235386A patent/IL235386A0/en unknown
-
2015
- 2015-03-24 HK HK15103006.9A patent/HK1202431A1/xx unknown
-
2016
- 2016-11-14 US US15/350,801 patent/US10058610B2/en not_active Expired - Fee Related
-
2018
- 2018-08-08 US US16/058,086 patent/US20180344846A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2013255537B2 (en) | 2018-02-15 |
IL235386A0 (en) | 2014-12-31 |
EP2844675B1 (fr) | 2019-01-02 |
EP2844675A2 (fr) | 2015-03-11 |
US20180344846A1 (en) | 2018-12-06 |
WO2013164689A8 (fr) | 2014-10-16 |
KR101933990B1 (ko) | 2018-12-31 |
JP6325527B2 (ja) | 2018-05-16 |
CN104428318A (zh) | 2015-03-18 |
US10058610B2 (en) | 2018-08-28 |
JP2015517300A (ja) | 2015-06-22 |
US20170165365A1 (en) | 2017-06-15 |
US9527913B2 (en) | 2016-12-27 |
AU2013255537A1 (en) | 2014-11-13 |
KR20150018528A (ko) | 2015-02-23 |
WO2013164689A2 (fr) | 2013-11-07 |
CA2872226A1 (fr) | 2013-11-07 |
MX358728B (es) | 2018-09-03 |
US20150086478A1 (en) | 2015-03-26 |
MX2014013213A (es) | 2015-06-05 |
WO2013164689A3 (fr) | 2014-03-13 |
CN104428318B (zh) | 2018-09-25 |
BR112014027291A2 (pt) | 2017-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1202431A1 (en) | Humanized pan-her antibody compositions pan-her | |
IL264558A (en) | Anti–il–23p19 antibodies | |
HK1209137A1 (en) | Humanized tau antibody tau | |
HK1203146A1 (en) | Antibody formulation | |
HK1204571A1 (en) | Protease-regulated antibodies | |
IL235042B (en) | Anti–fcrn antibodies | |
EP2922874A4 (fr) | Anticorps bispécifiques | |
ZA201406227B (en) | Humanized antibodies that recognize alpha-synuclein | |
IL236259A0 (en) | Anti 15–siglec antibodies | |
EP2930240A4 (fr) | Anticorps anti-folr1 | |
ZA201407316B (en) | Anti-fgfr2 antibody | |
EP2832855A4 (fr) | Nouvel anticorps anti-siglec-15 | |
EP2826790A4 (fr) | Anticorps anti-gremlin 1 | |
ZA201407079B (en) | Cdr-modified anti-siglec-15 antibody | |
EP2694539A4 (fr) | Compositions d'anticorps polyclonaux | |
HK1210186A1 (en) | Anti-h7cr antibodies h7cr | |
PL2935330T3 (pl) | Przeciwciała przeciw notch3 | |
GB201220242D0 (en) | Antibody | |
EP2848633A4 (fr) | Anticorps anti-cxadr | |
EP2811018A4 (fr) | ANTI-CORPS ANTI-sAPPß | |
IL235188A0 (en) | Antibodies against c-pdgf |